This story was first published in digitalhealth.net
MHRA recalls batches of Irbesartan
The Medicines and Healthcare Products Regulatory Agency (MHRA) has recalled 3 batches of Irbesartan, used to treat blood pressure, heart attacks and heart failures.
The recall is taking place as part of the continued investigation into potential N nitrosodiethylamine (NDEA) contamination of sartan containing medicines, a class of medicine to treat blood pressure and heart attacks and heart failures.
The affected batches can be viewed here.
MHRA twice recalled Irbesartan containing products in early and late January 2019 after testing revealed possible NDEA contamination.
The investigation into possible contamination began in 2018, after another impurity, N-nitrosodimethylamine (NDMA), was identified as part of the manufacturing process in a valsartan active substance manufactured at one facility based in China. NDEA was discovered after further testing.
Last year MHRA recalled batches of valsartan to pharmacy level in July and November after due to possible NDMA contamination.
The MHRA continues to monitor the situation alongside the European Medicines Agency (EMA) and the European Directorate for the Quality of Medicines (EDQM).
Dr Sam Atkinson MHRA’s Director of the Inspection, Enforcement and Standards Division said:
"Today’s Irbesartan recall shows we are continuing to investigate potential contamination of sartan containing medicines. There is no evidence at present that medicines containing NDMA or NDEA have caused any harm to patients the recall is occuring as a precaution.
"Because of the risk associated with suddenly stopping high blood pressure medication, continue to take your medicines as prescribed by your doctor.”
Latest News
16/02/2024 - 12:56
Hammersmith and Fulham Council has created a new alliance intended to clean dirty air and improve residents' health.
16/02/2024 - 10:44
Two million more GP appointments a month are being delivered for patients compared to the same month before the pandemic as part of the NHS primary care access recovery plan according to new NHS data.
15/02/2024 - 10:26
The Welsh Government has provided innovation funding of £380,000 to support two projects utilising technology in domiciliary care.
15/02/2024 - 10:13
The new Scottish health secretary has met with frontline staff at Queen Elizabeth University Hospital in Glasgow.
14/02/2024 - 10:27
The North East London NHS Foundation Trust (NELFT) has appointed three new Executive Directors to the Trust Board.
Product Features
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Supplier Profiles
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Latest Features
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly
